ID   HT-144
AC   CVCL_0318
SY   HT 144; HT144; HT144-mel; HT144mel
DR   BTO; BTO:0001406
DR   CLO; CLO_0004280
DR   EFO; EFO_0006443
DR   MCCL; MCC:0000211
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-63
DR   BioGRID_ORCS_Cell_line; 646
DR   BioSample; SAMN03472749
DR   BioSample; SAMN10988126
DR   cancercelllines; CVCL_0318
DR   Cell_Model_Passport; SIDM00695
DR   CGH-DB; 9314-4
DR   ChEMBL-Cells; CHEMBL3308870
DR   ChEMBL-Targets; CHEMBL2366291
DR   Cosmic; 687436
DR   Cosmic; 889003
DR   Cosmic; 905227
DR   Cosmic; 907067
DR   Cosmic; 928717
DR   Cosmic; 929192
DR   Cosmic; 932999
DR   Cosmic; 1022276
DR   Cosmic; 1028800
DR   Cosmic; 1102379
DR   Cosmic; 1155271
DR   Cosmic; 1477411
DR   Cosmic; 2159445
DR   Cosmic; 2651883
DR   Cosmic-CLP; 907067
DR   DepMap; ACH-000322
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 907067
DR   GEO; GSM162902
DR   GEO; GSM219028
DR   GEO; GSM887140
DR   GEO; GSM888211
DR   GEO; GSM1669912
DR   GEO; GSM1671957
DR   GEO; GSM1671964
DR   GEO; GSM1671976
DR   GEO; GSM1671980
DR   GEO; GSM1671984
DR   GEO; GSM1671985
DR   GEO; GSM1671988
DR   GEO; GSM1671993
DR   GEO; GSM1672009
DR   GEO; GSM1672016
DR   GEO; GSM1672018
DR   GEO; GSM1672020
DR   GEO; GSM1672021
DR   GEO; GSM1672026
DR   GEO; GSM1672029
DR   GEO; GSM1672045
DR   GEO; GSM1672059
DR   GEO; GSM1672063
DR   GEO; GSM3039508
DR   IARC_TP53; 21381
DR   LiGeA; CCLE_917
DR   LINCS_LDP; LCL-1273
DR   PharmacoDB; HT144_629_2019
DR   PRIDE; PXD002192
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0318
DR   PubChem_Cell_line; CVCL_0318
DR   Wikidata; Q54896505
RX   DOI=10.1007/978-1-4757-1647-4_5;
RX   DOI=10.1007/BF00199208;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=3518877;
RX   PubMed=6935474;
RX   PubMed=7017212;
RX   PubMed=7459858;
RX   PubMed=9354451;
RX   PubMed=10752474;
RX   PubMed=10338330;
RX   PubMed=12068308;
RX   PubMed=14692828;
RX   PubMed=14871852;
RX   PubMed=15048078;
RX   PubMed=15467732;
RX   PubMed=17363583;
RX   PubMed=17516929;
RX   PubMed=20164919;
RX   PubMed=21654344;
RX   PubMed=22383533;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=26405815;
RX   PubMed=26589293;
RX   PubMed=26673621;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   http://faculty.washington.edu/trawets/archive/Human/skin/ht144/index.html
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/ht-144-human-melanoma-cell-line
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-544.
CC   Population: Caucasian.
CC   HLA typing: A*01,24; B*13; C*03 (ATCC=HTB-63).
CC   HLA typing: A*01:01,24:02; B*15:01,57:01; C*03:03,06:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451; PubMed=17363583).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17363583).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=12068308; PubMed=15048078; PubMed=15467732; PubMed=17363583; PubMed=22383533; PubMed=26405815; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.49%; East Asian, North=0.47%; East Asian, South=0%; South Asian=0%; European, North=73.18%; European, South=25.86% (PubMed=30894373).
CC   Misspelling: HT-114; Cosmic=929192.
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
ST   Source(s): ATCC; Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11,12
ST   D16S539: 12,13
ST   D5S818: 11,13
ST   D7S820: 11
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   29Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 43
//
RX   DOI=10.1007/978-1-4757-1647-4_5;
RA   Fogh J., Trempe G.L.;
RT   "New human tumor cell lines.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York (1975).
//
RX   DOI=10.1007/BF00199208;
RA   Bruggen J., Sorg C., Macher E.;
RT   "Membrane associated antigens of human malignant melanoma V:
RT   Serological typing of cell lines using antisera from nonhuman
RT   primates.";
RL   Cancer Immunol. Immunother. 5:53-62(1978).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
//
RX   PubMed=7017212; DOI=10.1093/jnci/66.6.1003;
RA   Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.;
RT   "HLA-A, B, C and DR alloantigen expression on forty-six cultured human
RT   tumor cell lines.";
RL   J. Natl. Cancer Inst. 66:1003-1012(1981).
//
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
//
RX   PubMed=9354451;
RA   Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M.,
RA   Gabrielli B.G., Parsons P.G., Hayward N.K.;
RT   "CDKN2A/p16 is inactivated in most melanoma cell lines.";
RL   Cancer Res. 57:4868-4875(1997).
//
RX   PubMed=10752474; DOI=10.1007/s002620050015;
RA   Slingluff C.L. Jr., Colella T.A., Thompson L., Graham D.D.,
RA   Skipper J.C.A., Caldwell J., Brinckerhoff L., Kittlesen D.J.,
RA   Deacon D.H., Oei C., Harthun N.L., Huczko E.L., Hunt D.F.,
RA   Darrow T.L., Engelhard V.H.;
RT   "Melanomas with concordant loss of multiple melanocytic
RT   differentiation proteins: immune escape that may be overcome by
RT   targeting unique or undefined antigens.";
RL   Cancer Immunol. Immunother. 48:661-672(2000).
//
RX   PubMed=10338330; DOI=10.1097/00008390-199902000-00003;
RA   Rizos H., Darmanian A.P., Indsto J.O., Shannon J.A., Kefford R.F.,
RA   Mann G.J.;
RT   "Multiple abnormalities of the p16INK4a-pRb regulatory pathway in
RT   cultured melanoma cells.";
RL   Melanoma Res. 9:10-19(1999).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=14692828; DOI=10.1290/1543-706X(2004)40<35:COHMCL>2.0.CO;2;
RA   Quinones L.G., Garcia-Castro I.;
RT   "Characterization of human melanoma cell lines according to their
RT   migratory properties in vitro.";
RL   In Vitro Cell. Dev. Biol. Anim. 40:35-42(2004).
//
RX   PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209;
RA   Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J.,
RA   Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.;
RT   "Identification of novel and widely expressed cancer/testis gene
RT   isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to
RT   melanoma.";
RL   Cancer Res. 64:1157-1163(2004).
//
RX   PubMed=15048078; DOI=10.1038/sj.onc.1207563;
RA   Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M.,
RA   Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L.,
RA   Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G.,
RA   Meltzer P.S., Ringner M., Hayward N.K.;
RT   "Microarray expression profiling in melanoma reveals a BRAF mutation
RT   signature.";
RL   Oncogene 23:4060-4067(2004).
//
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
//
RX   PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152;
RA   Stark M.S., Hayward N.K.;
RT   "Genome-wide loss of heterozygosity and copy number analysis in
RT   melanoma using high-density single-nucleotide polymorphism arrays.";
RL   Cancer Res. 67:2632-2642(2007).
//
RX   PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x;
RA   Johansson P., Pavey S., Hayward N.K.;
RT   "Confirmation of a BRAF mutation-associated gene expression signature
RT   in melanoma.";
RL   Pigment Cell Res. 20:216-221(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21654344; DOI=10.1097/CMR.0b013e328343a1d6;
RA   Molhoek K.R., Shada A.L., Smolkin M., Chowbina S., Papin J.,
RA   Brautigan D.L., Slingluff C.L. Jr.;
RT   "Comprehensive analysis of receptor tyrosine kinase activation in
RT   human melanomas reveals autocrine signaling through IGF-1R.";
RL   Melanoma Res. 21:274-284(2011).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26405815; DOI=10.1371/journal.pone.0138210;
RA   Capaldo B.J., Roller D.G., Axelrod M.J., Koeppel A.F., Petricoin E.F. III,
RA   Slingluff C.L. Jr., Weber M.J., Mackey A.J., Gioeli D., Bekiranov S.;
RT   "Systems analysis of adaptive responses to MAP kinase pathway blockade
RT   in BRAF mutant melanoma.";
RL   PLoS ONE 10:E0138210-E0138210(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26673621; DOI=10.18632/oncotarget.6548;
RA   Roller D.G., Capaldo B.J., Bekiranov S., Mackey A.J., Conaway M.R.,
RA   Petricoin E.F. III, Gioeli D., Weber M.J.;
RT   "Combinatorial drug screening and molecular profiling reveal diverse
RT   mechanisms of intrinsic and adaptive resistance to BRAF inhibition in
RT   V600E BRAF mutant melanomas.";
RL   Oncotarget 7:2734-2753(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//